Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
ITGAX Biologics Sequence Review Report 2026: Integrin alpha-X Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGAX protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ITGAL Biologics Sequence Review Report 2026: Integrin alpha-L Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGAL protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD22 Biologics Sequence Review Report 2026: B-cell receptor CD22 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD22 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD33 Biologics Sequence Review Report 2026: Myeloid cell surface antigen CD33 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD33 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD53 Biologics Sequence Review Report 2026: Leukocyte surface antigen CD53 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD53 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ITGB6 Biologics Sequence Review Report 2026: Integrin beta-6 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ITGB5 Biologics Sequence Review Report 2026: Integrin beta-5 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ITGA2 Biologics Sequence Review Report 2026: Integrin alpha-2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PTPRC Biologics Sequence Review Report 2026: Receptor-type tyrosine-protein phosphatase C Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PTPRC protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CXCR5 Biologics Sequence Review Report 2026: C-X-C chemokine receptor type 5 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CXCR5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCR7 Biologics Sequence Review Report 2026: C-C chemokine receptor type 7 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CCR7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CCR1 Biologics Sequence Review Report 2026: C-C chemokine receptor type 1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CCR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
948
949
950
951
952
>>
2260
>